Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Interest & Investment Income: 2021-2024

Historic Interest & Investment Income for NewAmsterdam Pharma Co N.V (NAMS) over the last 4 years, with Dec 2024 value amounting to $16.9 million.

  • NewAmsterdam Pharma Co N.V's Interest & Investment Income rose 51.09% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.6 million, marking a year-over-year increase of 69.97%. This contributed to the annual value of $16.9 million for FY2024, which is 49.61% up from last year.
  • NewAmsterdam Pharma Co N.V's Interest & Investment Income amounted to $16.9 million in FY2024, which was up 49.61% from $11.3 million recorded in FY2023.
  • In the past 5 years, NewAmsterdam Pharma Co N.V's Interest & Investment Income registered a high of $16.9 million during FY2024, and its lowest value of $10,651 during FY2021.
  • Its 3-year average for Interest & Investment Income is $9.4 million, with a median of $11.3 million in 2023.
  • Data for NewAmsterdam Pharma Co N.V's Interest & Investment Income shows a peak YoY surged of 100,437.12% (in 2023) over the last 5 years.
  • NewAmsterdam Pharma Co N.V's Interest & Investment Income (Yearly) stood at $10,651 in 2021, then climbed by 5.37% to $11,223 in 2022, then surged by 100,437.12% to $11.3 million in 2023, then surged by 49.61% to $16.9 million in 2024.